• Rescuing Patient Enrollment for a Rare Mutation

    Case Studies
    Oct. 30, 2018

    A midsized pharmaceutical company was developing a treatment targeting newly diagnosed acute myeloid leukemia (AML) patients and selected Covance to support their global Phase III trial.

    A midsized pharmaceutical company was developing a treatment targeting newly diagnosed acute myeloid leukemia (AML) patients and selected Covance to support their global Phase III trial.